Cargando…
In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations
Pharmacological strategies to lower the viral load among patients suffering from severe diseases were researched in great detail during the SARS-CoV-2 outbreak. The viral protease M(pro) (3CLpro) is necessary for viral replication and is among the main therapeutic targets proposed, thus far. To stop...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854631/ https://www.ncbi.nlm.nih.gov/pubmed/36671672 http://dx.doi.org/10.3390/bioengineering10010100 |
_version_ | 1784873169034674176 |
---|---|
author | Ghufran, Mehreen Ullah, Mehran Khan, Haider Ali Ghufran, Sabreen Ayaz, Muhammad Siddiq, Muhammad Abbas, Syed Qamar Hassan, Syed Shams ul Bungau, Simona |
author_facet | Ghufran, Mehreen Ullah, Mehran Khan, Haider Ali Ghufran, Sabreen Ayaz, Muhammad Siddiq, Muhammad Abbas, Syed Qamar Hassan, Syed Shams ul Bungau, Simona |
author_sort | Ghufran, Mehreen |
collection | PubMed |
description | Pharmacological strategies to lower the viral load among patients suffering from severe diseases were researched in great detail during the SARS-CoV-2 outbreak. The viral protease M(pro) (3CLpro) is necessary for viral replication and is among the main therapeutic targets proposed, thus far. To stop the pandemic from spreading, researchers are working to find more effective M(pro) inhibitors against SARS-CoV-2. The 33.8 kDa M(pro) protease of SARS-CoV-2, being a nonhuman homologue, has the possibility of being utilized as a therapeutic target against coronaviruses. To develop drug-like compounds capable of preventing the replication of SARS-main CoV-2’s protease (M(pro)), a computer-aided drug design (CADD) approach is extremely viable. Using MOE, structure-based virtual screening (SBVS) of in-house and commercial databases was carried out using SARS-CoV-2 proteins. The most promising hits obtained during virtual screening (VS) were put through molecular docking with the help of MOE. The virtual screening yielded 3/5 hits (in-house database) and 56/66 hits (commercial databases). Finally, 3/5 hits (in-house database), 3/5 hits (ZINC database), and 2/7 hits (ChemBridge database) were chosen as potent lead compounds using various scaffolds due to their considerable binding affinity with M(pro) protein. The outcomes of SBVS were then validated using an analysis based on molecular dynamics simulation (MDS). The complexes’ stability was tested using MDS and post-MDS. The most promising candidates were found to exhibit a high capacity for fitting into the protein-binding pocket and interacting with the catalytic dyad. At least one of the scaffolds selected will possibly prove useful for future research. However, further scientific confirmation in the form of preclinical and clinical research is required before implementation. |
format | Online Article Text |
id | pubmed-9854631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98546312023-01-21 In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations Ghufran, Mehreen Ullah, Mehran Khan, Haider Ali Ghufran, Sabreen Ayaz, Muhammad Siddiq, Muhammad Abbas, Syed Qamar Hassan, Syed Shams ul Bungau, Simona Bioengineering (Basel) Article Pharmacological strategies to lower the viral load among patients suffering from severe diseases were researched in great detail during the SARS-CoV-2 outbreak. The viral protease M(pro) (3CLpro) is necessary for viral replication and is among the main therapeutic targets proposed, thus far. To stop the pandemic from spreading, researchers are working to find more effective M(pro) inhibitors against SARS-CoV-2. The 33.8 kDa M(pro) protease of SARS-CoV-2, being a nonhuman homologue, has the possibility of being utilized as a therapeutic target against coronaviruses. To develop drug-like compounds capable of preventing the replication of SARS-main CoV-2’s protease (M(pro)), a computer-aided drug design (CADD) approach is extremely viable. Using MOE, structure-based virtual screening (SBVS) of in-house and commercial databases was carried out using SARS-CoV-2 proteins. The most promising hits obtained during virtual screening (VS) were put through molecular docking with the help of MOE. The virtual screening yielded 3/5 hits (in-house database) and 56/66 hits (commercial databases). Finally, 3/5 hits (in-house database), 3/5 hits (ZINC database), and 2/7 hits (ChemBridge database) were chosen as potent lead compounds using various scaffolds due to their considerable binding affinity with M(pro) protein. The outcomes of SBVS were then validated using an analysis based on molecular dynamics simulation (MDS). The complexes’ stability was tested using MDS and post-MDS. The most promising candidates were found to exhibit a high capacity for fitting into the protein-binding pocket and interacting with the catalytic dyad. At least one of the scaffolds selected will possibly prove useful for future research. However, further scientific confirmation in the form of preclinical and clinical research is required before implementation. MDPI 2023-01-11 /pmc/articles/PMC9854631/ /pubmed/36671672 http://dx.doi.org/10.3390/bioengineering10010100 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ghufran, Mehreen Ullah, Mehran Khan, Haider Ali Ghufran, Sabreen Ayaz, Muhammad Siddiq, Muhammad Abbas, Syed Qamar Hassan, Syed Shams ul Bungau, Simona In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title | In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title_full | In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title_fullStr | In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title_full_unstemmed | In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title_short | In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations |
title_sort | in-silico lead druggable compounds identification against sars covid-19 main protease target from in-house, chembridge and zinc databases by structure-based virtual screening, molecular docking and molecular dynamics simulations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854631/ https://www.ncbi.nlm.nih.gov/pubmed/36671672 http://dx.doi.org/10.3390/bioengineering10010100 |
work_keys_str_mv | AT ghufranmehreen insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT ullahmehran insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT khanhaiderali insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT ghufransabreen insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT ayazmuhammad insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT siddiqmuhammad insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT abbassyedqamar insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT hassansyedshamsul insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations AT bungausimona insilicoleaddruggablecompoundsidentificationagainstsarscovid19mainproteasetargetfrominhousechembridgeandzincdatabasesbystructurebasedvirtualscreeningmoleculardockingandmoleculardynamicssimulations |